We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
It took Pfizer and Allergan less than 48 hours to nix their plan to build one of the world’s largest drugmakers, placing the blame squarely on the U.S. Treasury Department. Read More
Federal efforts to protect the drug supply chain continue to bear fruit, with the FDA’s Office of Criminal Investigations announcing criminal charges for another counterfeit operation. Read More
UK regulators have fined Pfizer $14,000 for failing to explain a questionable claim meant to justify price increases on the generic seizure medication Epanutin. Read More
It took a few days and a threatened contempt of Congress citation, but Valeant Pharmaceuticals International’s CEO J. Michael Pearson has agreed to meet with Senate officials investigating rising prescription drug prices. Read More
A federal court panel has resurrected a class action lawsuit against Pfizer that alleges the drug giant deceived shareholders by downplaying cardiovascular risks linked to Celebrex and Bextra. Read More
Valeant Pharmaceuticals is in Congress’ crosshairs again — with one lawmaker demanding the drugmaker turn over documents related to an investigation into the company’s relationship with Philidor Rx Services. Read More
A three-judge panel for the U.S. Court of Appeals for the Federal Circuit has upheld two Depomed patents, enabling it to resume its lawsuit against Purdue Pharma. Read More
The FTC is arguing that a district court erred in failing to apply the Supreme Court ruling in FTC v. Actavis in a pay-for-delay case involving GlaxoSmithKline’s Wellbutrin XL antidepressant. Read More